101 related articles for article (PubMed ID: 15471427)
1. Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study.
Suo Z; Karbovo E; Trope CG; Metodiev K; Nesland JM
Ultrastruct Pathol; 2004; 28(3):141-7. PubMed ID: 15471427
[TBL] [Abstract][Full Text] [Related]
2. Phyllodes tumor of the breast: EGFR family expression and relation to clinicopathological features.
Suo Z; Nesland JM
Ultrastruct Pathol; 2000; 24(6):371-81. PubMed ID: 11206334
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary.
Wang DP; Konishi I; Koshiyama M; Nanbu Y; Iwai T; Nonogaki H; Mori T; Fujii S
Virchows Arch A Pathol Anat Histopathol; 1992; 421(5):393-400. PubMed ID: 1360720
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas.
Halperin R; Zehavi S; Dar P; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(4):292-6. PubMed ID: 11695812
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma.
Halperin R; Zehavi S; Hadas E; Habler L; Bukovsky I; Schneider D
Int J Gynecol Pathol; 2001 Oct; 20(4):341-5. PubMed ID: 11603217
[TBL] [Abstract][Full Text] [Related]
6. Immunolocalization of epidermal growth factor receptor and c-erbB-2 oncogene product in human ovarian carcinoma.
Ito K; Sasano H; Ozawa N; Sato S; Silverberg SG; Yajima A
Int J Gynecol Pathol; 1992 Oct; 11(4):253-7. PubMed ID: 1356938
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.
Wang D; Konishi I; Koshiyama M; Mandai M; Nanbu Y; Ishikawa Y; Mori T; Fujii S
Cancer; 1993 Nov; 72(9):2628-37. PubMed ID: 8104681
[TBL] [Abstract][Full Text] [Related]
8. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases.
Raju U; Fine G; Greenawald KA; Ohorodnik JM
Hum Pathol; 1989 May; 20(5):426-36. PubMed ID: 2707793
[TBL] [Abstract][Full Text] [Related]
9. EGFR, HER2÷neu and Ki67 immunoexpression in serous ovarian tumors.
Marinaş MC; Mogoş G; Ciurea R; Mogoş DG
Rom J Morphol Embryol; 2012; 53(3):563-7. PubMed ID: 22990547
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms.
Harlozińska A; Bar JK; Sobańska E; Goluda M
Tumour Biol; 1998; 19(5):364-73. PubMed ID: 9701727
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
[TBL] [Abstract][Full Text] [Related]
12. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
13. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
14. Expression of cell regulatory proteins in ovarian borderline tumors.
van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
[TBL] [Abstract][Full Text] [Related]
15. Expression of the ErbB family of receptors in ovarian cancer.
Scoccia B; Lee YM; Niederberger C; Ilekis JV
J Soc Gynecol Investig; 1998; 5(3):161-5. PubMed ID: 9614647
[TBL] [Abstract][Full Text] [Related]
16. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
17. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content.
Prat J; Oliva E; Lerma E; Vaquero M; Matías-Guiu X
Cancer; 1994 Sep; 74(6):1778-83. PubMed ID: 7915964
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D.
Henzen-Logmans SC; Fieret EJ; Berns EM; van der Burg ME; Klijn JG; Foekens JA
Int J Cancer; 1994 May; 57(4):468-72. PubMed ID: 8181851
[TBL] [Abstract][Full Text] [Related]
19. Serous tumors of the ovary: ultrastructural observations.
Franchina M; Del Borrello E; Caruso A; Altavilla G
Eur J Gynaecol Oncol; 1992; 13(3):268-76. PubMed ID: 1618226
[TBL] [Abstract][Full Text] [Related]
20. IL-17A is elevated in sera of patients with poorly differentiated ovarian papillary serous cystadenocarcinoma.
Malekzadeh M; Dehaghani AS; Ghaderi A; Doroudchi M
Cancer Biomark; 2013 Jan; 13(6):417-25. PubMed ID: 24595078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
